Stocktoria
Polaryx Therapeutics, Inc. PLYX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2026-02-02
Polaryx Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| R&D expense | $6.3M | $2.8M |
| Operating income | -$7.8M | -$4.4M |
| Net income | -$9.0M | -$30.4M |
| EPS (diluted) | $-0.20 | $-0.89 |
| Operating cash flow | -$3.9M | -$2.6M |
| Cash & equivalents | $5.1M | $4.6M |
| Total assets | $5.2M | $5.0M |
| Total liabilities | $605,000 | $289,000 |
| Shareholders' equity | $4.6M | $4.7M |
Source: SEC EDGAR filings · CIK 0002075320 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.